Cape Drugs (Valgene Incorporated), Annapolis, MD

Is Cape Drugs (Valgene Incorporated) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Cape Drugs (Valgene Incorporated) hold a Maryland pharmacy license?

State pharmacy license records for Maryland are not checked: the board’s license verification is an interactive search, which this index does not use. This index reads only that state’s board actions. The Delaware Division of Professional Regulation also lists nonresident license A9-0002099 for Cape Drugs, ANNAPOLIS, MD, status Active, as of Nov 10, 2026.

Has Cape Drugs (Valgene Incorporated) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jan 13, 2023), 1 untitled letter (Jul 20, 2022) and 1 FMD-145 letter (Jan 13, 2023) for Cape Drugs (Valgene Incorporated). State board actions: no Maryland Board of Pharmacy action under this exact name and city was found in the Maryland Board of Pharmacy’s posted orders against permit holders that this index could read (actions dated Jan 2, 2007 to Oct 20, 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Valgene Incorporated; Cape Drugs
Location
Annapolis, MD
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jan 13, 2023
FDA Data Dashboard inspections
3 inspections: 1 OAI, 2 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 7 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Valgene Incorporated, (dba Cape Drugs), a 503A facility, with 4 dated actions.

Document
Jan 13, 2023Warning letter close-outWarning Letter Close Out Issued 01/13/2023Not linked by FDA
Jan 13, 2023FMD-145 letterFMD-145 Letter Issued 01/13/2023Not linked by FDA
Jul 20, 2022Untitled letterUntitled Letter Issued 07/20/2022FDA copy (archived)
Dec 2, 2021Form 483483 Issued 12/02/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Valgene Incorporated, Annapolis, MD (FEI number 3004562873), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 2, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30045628731159287
Jan 22, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30045628731038474
Oct 7, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004562873945407

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 7 numbered observations in all, across 2 inspections ending Jan 22, 2018 to Dec 2, 2021. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Nov 8, 2021 to Dec 2, 2021: 4 observations

Firm on the cover
Valgene Incorporated dba Cape Drugs, 1384 Cape St Claire Rd, Annapolis, MD 21409-5325
FEI number
3004562873
Establishment type on the cover
Producer of sterile and non-sterile drug products
FDA district office on the cover
11155 Dolfield Boulevard, Suit e 117 Owings Mills, MD 21117
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.

Specifically, on November 23, 2021, during daily cleaning following the completion of sterile production operations, the use of your disinfectant and sporicidal agent, <Redacted B4> in the ISO 5 classified laminar flow hood was not allowed to dwell the required <Redacted B4> contact time, per your procedures and the cleaning agent manufacturer's use directions. Most areas of the hood work surface had a drying time of less than <Redacted B4>

Observation 2

The ISO 5 classified aseptic processing areas had difficult to clean and particle-generating equipment or surface.

Specifically, your ISO 5 classified laminar airflow hood (LAFH) sits atop a bench which appears to be made of a wood-like material laminated on the top and sides. The bottom of the bench is not laminated, and the wood-like material is exposed within the ISO 7 classified "Sterile Prep" buffer room. Additionally, the front-right laminated corner of the bench is chipped such that the wood-like material is exposed, approximately less than one-half centimeter in diameter.

Use of the bench with exposed wood-like material was observed during production of Rx <Redacted B4> "POLYHEXAMETHYLENE HCL STERILE* 0.06% DROPS", lot 190413, on November 23, 2021.

Observation 3

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically, there are <Redacted B4>, <Redacted B4> located between your unclassified hallway and your ISO 7 classified buffer rooms <Redacted B4> leads to your "Sterile Prep" buffer room and <Redacted B4> to your "Chemo Prep" buffer room. According to RTM, Owner/Compounding Specialist, production materials used in the production of sterile products, are exchanged through these <Redacted B4>. As they are currently designed, these <Redacted B4> permit unclassified air to enter the ISO 7 classified area.

Use of the <Redacted B4> leading to the "Sterile Prep" buffer room was observed during production of Rx <Redacted B4> "POLYHEXAMETHYLENE HCL STERILE* 0.06% DROPS", lot 190413, on November 23, 2021.

Observation 4

ISO 5 classified areas were not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic operational conditions representative of your aseptic processing practices. Air visualization studies ("smoke studies") performed in July of 2021, in your ISO 5 classified laminar airflow hood (LAFH) and biological safety cabinet (BSC), did not demonstrate unidirectional airflow during representative sterile processing. Review of the smoke study video revealed gloved hands moving overtop the work bench, holding one syringe tip, without the additional materials typically used in sterile production such as vials, syringes, and a beaker. For example, production of Rx <Redacted B4> "POLYHEXAMETHYLENE 1 HCL STERILE* 0.06% DROPS", lot 190413, on November 23, 2021, included a <Redacted B4> container, a Polyhexamethylene <Redacted B4> solution container <Redacted B4> syringes, and a <Redacted B4> through with <Redacted B4> method mixing operations occurred.

a Polyhexamethylene tb)(<l} solution container K6TT4n J 6)- rl)l syringes, and a[ 6,rl} !through with [o) (4) I method mixing operations occurred.

Inspection Jan 2, 2018 to Jan 22, 2018: 3 observations

Firm on the cover
Cape Drugs, 1384 Cape St. Claire Rd, Annapolis, MD 21409-5325
FEI number
3004562873
Establishment type on the cover
Producer of Non- Sterile Drug Products
FDA district office on the cover
6000 Metro Drive, Suite 101 Baltimore, MD 21215
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, your firm produces highly potent drugs that includes, but not limited to Progesterone, Testosterone, Estradiol, Estriol, or a combination of these drug products using powder Active Pharmaceutical Ingredients (APis) and other excipients. Utensils such as capsule-filling metal and plastic plates used in the compounding operations of these highly potent drugs are not dedicated and are not adequately cleaned with appropriate cleaning agents prior to use on non-potent drug substances. Further,

a) Your firm currently utilizes household dish liquid detergent and potable water for cleaning of utensils used in the processing of highly potent drug substances, including capsule-filling and related utensils.

b) No cleaning procedure has been established to demonstrate how cleaning of shared utensils used in the processing of drug substances should be performed to prevent cross-contamination.

Observation 2

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use and cleaning and maintenance.

Specifically, you failed to provide maintenance and qualification records for the <Redacted B4> powder-hoods that your firm uses to process drug products to ensure that they adequately operate as intended. Further, the powder-hoods are equipped with non-pharmaceutical grade filters <Redacted B4> which you failed to prevent from potentially cross-containinating other drug products. Moreover, the powder hoods are used to capsule fill or process both highly potent (Progesterone, Testosterone, Estradiol, etc.) and non-potent (Budesonide, Lidocaine, Benzocaine, etc.) drug products and these <Redacted B4> are not adequately designed to be cleaned in between capsule-filling operations of highly potent and non-potent drug substances.

Observation 3

Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.

Specifically, some of the oral and topical drug products compounded by your firm for human and veterinary use are made using <Redacted B4> water. Your firm has no documentation of any testing performed (analytical or microbiological) to show that the water at least/at minimum meets the specification for purified water. An example of a drug reconstituted with <Redacted B4> water and dispensed by your firm for human consumption includes:

a) Vancomycin 125mg/5mL <Redacted B4> Oral Solution, Lot# 123365, produced on 11/02/17

b) Vancomycin 250mg/5mL <Redacted B4> Oral Solution, Lot# 125714, produced on 12/15/17

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for Maryland are not checked: the board’s license verification is an interactive search, which this index does not use. This index reads only that state’s board actions. Board actions source.

What this covers: Orders and notices the Maryland Board of Pharmacy links on its Formal Disciplinary Actions page, read from each PDF: 2,109 documents listed, of which 1,337 are labeled with a person’s surname and initials (orders against pharmacists and technicians) and were not read; of the other 772, 328 had readable text, 438 scanned without a text layer and 6 that could not be downloaded. 312 name a permit holder rather than a pharmacist or technician; for 98 of them no city could be read from the document, so they cannot be matched to a page. Each is dated by the date on the board’s list, and the title and passage are copied from the PDF’s text layer, which for scanned orders is a machine reading of the page and can misread a letter, so open the document before relying on a quoted word. Maryland pharmacy permits themselves are not checked. 16 documents have no readable title. Actions in the data are dated Jan 2, 2007 to Oct 20, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0002099Non Resident PharmacyCape DrugsANNAPOLIS, MDActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.